Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by WILCOCK, G. K.
Right arrow Articles by ROYSTON, V. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WILCOCK, G. K.
Right arrow Articles by ROYSTON, V. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 Oxford University Press

research-article

An Evaluation of the Efficacy and Safety of Tetrahydroaminoacridine (THA) without Lecithin in the Treatment of Alzheimer's Disease

GORDON K. WILCOCK, DENISE J. SURMON, MARGARET SCOTT, MARY BOYLE, KATHARINE MULLIGAN, KYRA A. NEUBAUER, DESMOND O'NEILL and VIRGINIA H. ROYSTON

Department of Care of the Elderly, Frenchay Hospital Bristol BS16 1LE

Seventy-nine patients with probable Alzheimer's disease were enrolled into a double-blind, placebo-controlled cross-over study to assess the therapeutic effect and safety of THA (tetrahydroaminoacridine; tacrine) without concomitant lecithin administration. Forty-one patients completed the trial which consisted of two 12-week treatment phases separated by a 4-week wash-out period. Twenty-six subjects were withdrawn during the active treatment phase, mostly because of elevated transaminases or cholinergic side-effects, and ten during treatment with placebo.

Statistical analyses were conducted on two groups of patients; those completing the cross-over and those with at least one evaluation in the first treatment period. This latter analysis, using the last observation carried forward was used to approximate an intention-to-treat analysis. THA was favoured over placebo in all three primary outcome measures (MMSE, ADAS Non-cognitive Scale, and the Functional Life Scale), but the results did not reach statistical significance. THA was favoured over placebo in five of the seven secondary outcome measures, but for only two of these was statistical significance attained. In terms of a three-point or greater increase in MMSE score, three to four times as many subjects improved on THA as on placebo.

Received April 20, 1993;
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
N. Qizilbash, A. Whitehead, J. Higgins, G. Wilcock, L. Schneider, M. Farlow, and for the Dementia Trialists' Collaboration
Cholinesterase Inhibition for Alzheimer Disease: A Meta-analysis of the Tacrine Trials
JAMA, November 25, 1998; 280(20): 1777 - 1782.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
W W Pendlebury, P R Solomon, R Levy, C Roberts, P Makela, J Ford, C Truman, G K Wilcock, G A Broe, H Creasey, et al.
Tacrine and lecithin in Alzheimer's disease Tacrine is safe and effective
BMJ, June 4, 1994; 308(6942): 1506 - 1507.
[Full Text]

Home page
 BMJHome page
E Byrne and T Arie
Tetrahydroaminoacridine and Alzheimer's disease
BMJ, April 2, 1994; 308(6933): 868 - 869.
[Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.